120017
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
放疗联合 PD-1 抑制剂和靶向治疗不可切除肝细胞癌的有效性和安全性：一项回顾性真实世界多中心研究
Authors Xu WX, Gao SM , Zheng PC , Chen JL , Guo XY, Li C, Chen XL, Tang SN, Nie YY, Lu LB, Chen X
Received 17 October 2025
Accepted for publication 14 January 2026
Published 11 February 2026 Volume 2026:13 572797
DOI https://doi.org/10.2147/JHC.S572797
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Editor who approved publication: Dr Mohamed Shaker
Wei-Xuan Xu,1,* Si-Miao Gao,1,* Pei-Chan Zheng,2,* Jia-Lin Chen,1 Xin-Ying Guo,1 Cheng Li,1 Xiang-Long Chen,1 Si-Ning Tang,1 Yun-Ying Nie,1 Lin-Bin Lu,1 Xiong Chen1
1Department of Oncology, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, Fujian, People’s Republic of China; 2Fujian Center for Safety Evaluation of New Drug, Fujian Key Laboratory of Natural Medicine Fharmacology, Fujian Medical University, Fuzhou, Fujian, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Lin-Bin Lu, Email drxiaolin@fjmu.edu.cn Xiong Chen, Email cxiongzpc@fjmu.edu.cn
Purpose: Real-world evidence concerning the triple-combination regimens of radiotherapy (RT), PD-1 inhibitors, and targeted therapy for unresectable hepatocellular carcinoma (uHCC) is limited. This study evaluated the efficacy and safety of this combination and identified predictors of survival.
Patients and Methods: In this multicenter retrospective study, 122 consecutive patients with uHCC received RT combined with PD-1 inhibitors and targeted therapy were analyzed. Objective response rate (ORR), disease control rate (DCR), overall survival (OS), progression-free survival (PFS) and treatment-related adverse events (TRAEs) were calculated. Cox regression was used to identify independent prognostic factors. Subgroup analysis explored the association between immunotherapy cycles and overall survival across tumor response stratification.
Results: The cohort included 53 patients with extrahepatic metastases and 48 with macrovascular invasion. Patients received RT with a median dose of 45 Gy (range: 32.3– 58.5 Gy). Median follow-up was 14.2 months. According to the modified response evaluation criteria in solid tumor (mRECIST), the ORR and DCR were 18.85% and 73.78%, respectively. The median OS was 19.0 months (95% CI: 17.8– 23.4 months), and the median PFS was 7.2 months (95% CI: 5.5– 10.9 months). TRAEs of any grade occurred in 93 patients (76.23%), with grade 3– 4 TRAEs observed in 40 patients (32.79%). No treatment-related death was observed. Multivariate analysis identified elevated AFP and higher mALBI grade as independent risk factors for OS. Higher mALBI grade and neutrophil-to-lymphocyte ratio (NLR) predicted worse PFS. Exploratory analysis suggested extending immunotherapy duration may improve OS in patients with stable disease.
Conclusion: The triple-combination of RT, PD-1 inhibitors, and targeted therapy demonstrates promising survival benefits and a manageable toxicity profile for uHCC. Baseline AFP, liver function, NLR level are key determinants of survival, supporting the individualized application of this multimodal approach.
Keywords: unresectable hepatocellular carcinoma, radiotherapy, PD-1 inhibitors, targeted therapy, multicenter study
1Department of Oncology, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, Fujian, People’s Republic of China; 2Fujian Center for Safety Evaluation of New Drug, Fujian Key Laboratory of Natural Medicine Fharmacology, Fujian Medical University, Fuzhou, Fujian, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Lin-Bin Lu, Email drxiaolin@fjmu.edu.cn Xiong Chen, Email cxiongzpc@fjmu.edu.cn
Purpose: Real-world evidence concerning the triple-combination regimens of radiotherapy (RT), PD-1 inhibitors, and targeted therapy for unresectable hepatocellular carcinoma (uHCC) is limited. This study evaluated the efficacy and safety of this combination and identified predictors of survival.
Patients and Methods: In this multicenter retrospective study, 122 consecutive patients with uHCC received RT combined with PD-1 inhibitors and targeted therapy were analyzed. Objective response rate (ORR), disease control rate (DCR), overall survival (OS), progression-free survival (PFS) and treatment-related adverse events (TRAEs) were calculated. Cox regression was used to identify independent prognostic factors. Subgroup analysis explored the association between immunotherapy cycles and overall survival across tumor response stratification.
Results: The cohort included 53 patients with extrahepatic metastases and 48 with macrovascular invasion. Patients received RT with a median dose of 45 Gy (range: 32.3– 58.5 Gy). Median follow-up was 14.2 months. According to the modified response evaluation criteria in solid tumor (mRECIST), the ORR and DCR were 18.85% and 73.78%, respectively. The median OS was 19.0 months (95% CI: 17.8– 23.4 months), and the median PFS was 7.2 months (95% CI: 5.5– 10.9 months). TRAEs of any grade occurred in 93 patients (76.23%), with grade 3– 4 TRAEs observed in 40 patients (32.79%). No treatment-related death was observed. Multivariate analysis identified elevated AFP and higher mALBI grade as independent risk factors for OS. Higher mALBI grade and neutrophil-to-lymphocyte ratio (NLR) predicted worse PFS. Exploratory analysis suggested extending immunotherapy duration may improve OS in patients with stable disease.
Conclusion: The triple-combination of RT, PD-1 inhibitors, and targeted therapy demonstrates promising survival benefits and a manageable toxicity profile for uHCC. Baseline AFP, liver function, NLR level are key determinants of survival, supporting the individualized application of this multimodal approach.
Keywords: unresectable hepatocellular carcinoma, radiotherapy, PD-1 inhibitors, targeted therapy, multicenter study